IMM2901

N/A

Report date: 2023/02/13 16:09:28

Base Information

Drug NameIMM2901

Drug Alias NameIMM-2901IMM2901

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Cluster of differentiation 47Anti-HER2

TargetsCluster of differentiation 47Receptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A